Tempus AI has launched the next generation of its Lens platform, an agentic AI system designed to accelerate oncology drug development and research. This advanced version integrates Tempus' vast library of de-identified multimodal data with AI tools and high-performance computing to provide faster, more actionable insights for biopharmaceutical companies.
The platform enables drug development teams to more efficiently design clinical trials, identify specific patient subgroups, and generate crucial evidence. New features include "Co-scientist" agents that can understand complex hypotheses phrased in plain language and then execute analyses against more than 8.5 million patient records to deliver results in minutes. The Lens platform is already used by 19 of the top 20 largest biopharma companies.